Lisaftoclax
A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 3
- Enrollment
- 464 patients (estimated)
- Sponsors
- Ascentage Pharma Group Inc.
- Tags
- BCL-2 Inhibitor, Placebo, Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 2010
- NCT Identifier
- NCT06641414
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.